FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1053-1054 March 4, 2004 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Skolnik, P. R. Related Article by Robbins, G. K. PubMed Citation

To the Editor: Skolnik (Dec. 11 issue),¹ in his editorial accompanying the report by Robbins et al.² on initial therapy for human immunodeficiency virus (HIV) infection, suggests that nelfinavir, which was a component of the antiretroviral regimens used in the study by Robbins et al., may be less effective than other protease inhibitors for the initiation of HIV treatment. However, there was no meaningful difference between efavirenz and nelfinavir when combined with stavudine and didanosine. Moreover, after a median of 2.3 years, the percentage of successfully treated patients who started to take nelfinavir or efavirenz was virtually identical: nelfinavir, 170 . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.